Palisade Bio advances PALI-2108 toward Phase 2 trials in ulcerative colitis, Crohn's disease

Palisade Bio, Inc. reported financial results for the quarter ended June 30, 2026 on August 10, 2026, alongside an update on its lead candidate PALI-2108, an oral PDE4 inhibitor prodrug for inflammatory bowel disease. During the quarter, the company finished regulatory and operational work needed to support starting the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026.¹

The company pointed to its completed Phase 1 trial as the basis for moving forward. That Phase 1 trial enrolled five patients with ulcerative colitis and five with fibrostenotic Crohn's disease.¹ Among the ulcerative colitis patients, five of five achieved clinical response and two of five achieved clinical remission by Modified Mayo Score.¹ In the fibrostenotic Crohn's disease group, PALI-2108 cut the mean SES-CD score by about 47.5%, a 3.8-point drop, with two of five patients reaching both endoscopic response and remission on that scale.¹

On timing, the company said it received FDA clearance of the IND for PALI-2108, expects the Phase 2 UC trial to start in the second half of 2026, and expects a primary efficacy readout in the second half of 2027.¹ For Crohn's disease, it plans to submit an IND in the second half of 2026, target trial start in the first quarter of 2027, and expects a primary efficacy readout in early 2028.¹

On finances, net loss was $10.6 million, or $0.05 per share, for the three months ended June 30, 2026, compared with a net loss of $2.8 million, or $0.58 per share, a year earlier.¹ As of June 30, 2026, the company held $125.2 million in cash and cash equivalents, which it said should fund operations through the planned UC and CD Phase 2 efficacy readouts.¹